• Wrong document? Swap it for free
  • Written by students who passed
  • Immediately available after payment
  • Read online or as PDF
Sell
Where do you study
Your language
Document preview thumbnail
Preview 4 out of 272 pages
Summary

Complete summary of the virology course

Document preview thumbnail
Preview 4 out of 272 pages

in depth complete summary of all lectures in the virology course including the discussion of the different viruses

Content preview

TABLE OF CONTENTS

An introduction to virology ..........................................................................................................................................................................12
What are viruses?.......................................................................................................................................................................................................... 12

Astonishing number of viruses on Earth à Viruses are everywhere ............................................................................................................................... 12

The human genome contains remnants of viral genetic material .................................................................................................................................... 14

Viruses are small ........................................................................................................................................................................................................... 14

Viruses are diverse in structure ...................................................................................................................................................................................... 14

All viruses are obligatory parasites (they need to get into a cell !) .................................................................................................................................. 15

Virus replication............................................................................................................................................................................................................ 16

Viruses have high genome evolution rates ..................................................................................................................................................................... 17

So, are viruses dead or alive........................................................................................................................................................................................... 18
Most important reasons to exclude viruses from the tree of life ........................................................................................................................................................................................... 18
There are no ancestral viral lineages: ..................................................................................................................................................................................................................................... 18
Viruses don’t have a structure derived from a common ancestor: ......................................................................................................................................................................................... 18

Origin of viruses à Three traditional scenario’s: ............................................................................................................................................................ 19

A typical virus genome à it is a nucleic acid code .......................................................................................................................................................... 20

A chimeric origin of viruses............................................................................................................................................................................................ 20

Five hallmark viral replication genes .............................................................................................................................................................................. 21

Cellular ancestry of capsids............................................................................................................................................................................................ 21

A brief history of virology .............................................................................................................................................................................................. 22

Koch’s postulates !!! to affirm the causes of infectious diseases ...................................................................................................................................... 22

21st century revised version of Koch’s postulates .........................................................................................................................................23
Classification of viruses.................................................................................................................................................................................................. 23

!!!!!!!!! THE BALTIMORE SYSTEM ................................................................................................................................................................................... 24
Definitions/rules underlying the Baltimore system ................................................................................................................................................................................................................ 25
Class I: dsDNA genomes and gapped dsDNA genomes .......................................................................................................................................................................................................... 26
Viruses with dsDNA genomes ................................................................................................................................................................................................................................................ 26
Class II: ssDNA genomes ........................................................................................................................................................................................................................................................ 27
Viruses with ssDNA genomes ................................................................................................................................................................................................................................................. 27
Viruses with RNA genomes .................................................................................................................................................................................................................................................... 27
Class III: dsRNA genomes ....................................................................................................................................................................................................................................................... 28
Viruses with dsRNA genomes ................................................................................................................................................................................................................................................ 28
Class IV: ss(+)RNA genomes ................................................................................................................................................................................................................................................... 28
Class V: ss(-)RNA genomes ..................................................................................................................................................................................................................................................... 29
Class VI: ss(+)RNA genomes with a DNA intermediate ........................................................................................................................................................................................................... 29
Class VII: dsDNA genomes with a RNA intermediate .............................................................................................................................................................................................................. 30
Summary of 7 genome classes according to Baltimore .......................................................................................................................................................................................................... 31

The virology toolbox ...................................................................................................................................................................................33
How can we say that a virus is present or not? ............................................................................................................................................................... 33

Virus isolation and propagation ..................................................................................................................................................................................... 33

Some important definitions and concepts ...................................................................................................................................................................... 33

Virus isolation and propagation in cell culture................................................................................................................................................................ 35

Viruses can induce formation of synctytia ...................................................................................................................................................................... 35

Determining the number of viruses in a sample à 2 main methods ............................................................................................................................... 35
Multiplicity of infection (MOI) ................................................................................................................................................................................................................................................ 37


1

, Physical measurements of virus particles ....................................................................................................................................................................... 38

Electron microscopy ...................................................................................................................................................................................................... 38

Detecting viral antigens and antiviral antibodies ............................................................................................................................................................ 39

introduction part 2: Virus structures ...........................................................................................................................................................40
A typical virus genome .................................................................................................................................................................................................. 40
Virus particles are made up from structural proteins Functions of structural proteins: ........................................................................................................................................................ 40
From larger to smaller blocks................................................................................................................................................................................................................................................. 40
Virus particles are metastable ................................................................................................................................................................................................................................................ 40
3 basic virus structures .......................................................................................................................................................................................................................................................... 41
Symmetry is key to build virus particles Watson and Crick seminal observations: ................................................................................................................................................................ 41
Virus particles are metastable ................................................................................................................................................................................................................................................ 41
Many capsid proteins are self-assembling in VLP (virus-like-particles) ................................................................................................................................................................................... 41

Helical symmetry ........................................................................................................................................................................................................... 42

Icosahedral symmetry (it is like crystals) ........................................................................................................................................................................ 42
Simple icosahedral capsid ...................................................................................................................................................................................................................................................... 42

Capsids can be covered by host-derived lipid membranes (! This is not always) .............................................................................................................. 43
why would a virus get an (extra) envelop (instead of a just capside)? .................................................................................................................................................................................... 43

Viral envelope ............................................................................................................................................................................................................... 44
Viral envelope glycoprotein.................................................................................................................................................................................................................................................... 44

Complex symmetry........................................................................................................................................................................................................ 44

Replication cycles ......................................................................................................................................................................................................... 46
Steps in virus replication ........................................................................................................................................................................................................................................................ 46

Virus attachment and entry ........................................................................................................................................................................................... 46

Cellular receptors for viruses ......................................................................................................................................................................................... 48
Criteria to identify virus receptors à EXAM QUESTION ......................................................................................................................................................................................................... 48

Adhesion receptors and entry receptors ........................................................................................................................................................................ 48

Virus attachment to host glycan polysaccharide ............................................................................................................................................................. 50

Virus attachment to host lectin ...................................................................................................................................................................................... 50

Strategies of how viruses enter cells .............................................................................................................................................................................. 50
Fusion is a regulated process ................................................................................................................................................................................................................................................. 50
Fusion of viral and plasma membranes at the cell surface (receptor mediated) .................................................................................................................................................................... 50
Fusion of virus membrane with host endosomal membrane ................................................................................................................................................................................................. 50

Non-enveloped virus entry and genome release ............................................................................................................................................................ 53

Active transportation through the cytosol ...................................................................................................................................................................... 53

Modes of nuclear entry (mostly DNA viruses) ................................................................................................................................................................ 53

Genome transcription and translation ........................................................................................................................................................................... 55
Some definitions .................................................................................................................................................................................................................................................................... 55

Rules for viral RNA synthesis ......................................................................................................................................................................................... 55

Universal rules for RNA-directed RNA synthesis ............................................................................................................................................................. 55
RdRp initiates RNA synthesis in two ways .............................................................................................................................................................................................................................. 56
Single stranded (+)RNA viruses .............................................................................................................................................................................................................................................. 57
Single stranded (-)RNA viruses ............................................................................................................................................................................................................................................... 57
dsRNA viruses (contain both + and – strands) ........................................................................................................................................................................................................................ 58

dsDNA transcription in DNA viruses ............................................................................................................................................................................... 58

Cap snatching by influenza virus .................................................................................................................................................................................... 59

Viral mRNA’s are polyadenylated at the 3’ end ............................................................................................................................................................... 59

Initiation of translation in eukaryotes ............................................................................................................................................................................ 59


2

, Initiation of translation of uncapped mRNA ................................................................................................................................................................... 59
What does IRES do? .............................................................................................................................................................................................................................................................. 60

Monocistronic and polycistronic mRNA’s ....................................................................................................................................................................... 60

Viruses do all the same things that our proteins do à Post-translational modifications ................................................................................................. 62

Genome replication ...................................................................................................................................................................................................... 64
Locations of virus genome replication in eukaryotic cells ....................................................................................................................................................................................................... 64
Initiation of genome replication ............................................................................................................................................................................................................................................. 64
DNA strand displacement replication ..................................................................................................................................................................................................................................... 66
Key enzymes in RNA virus genome replication ....................................................................................................................................................................................................................... 66
Viral factories......................................................................................................................................................................................................................................................................... 67
ss(-)RNA virus replication (Filoviruses) ................................................................................................................................................................................................................................... 67

Reverse transcription .................................................................................................................................................................................................... 68

introduction part 3 .....................................................................................................................................................................................69
Assembly and exit ......................................................................................................................................................................................................... 69

The structure of a virion determines how it is formed .................................................................................................................................................... 70

All virions complete a common set of assembly reactions .............................................................................................................................................. 70

Moving cargo around the cytoplasm .............................................................................................................................................................................. 70

How to get viral proteins in the right place for assembly? .............................................................................................................................................. 71

Virus assembly is an ordered proces .............................................................................................................................................................................. 71

(Nucleo)capsid assembly and genome packaging ........................................................................................................................................................... 71

Three strategies for making sub-assemblies ................................................................................................................................................................... 72

Some viruses assemble their capsid in the nucleus......................................................................................................................................................... 72

Nuclear exit of the viral genome or nuclear capsid ......................................................................................................................................................... 73
Assisted genome export through nuclear pores..................................................................................................................................................................................................................... 73
Genome export through nuclear egress (Herpesviruses) ....................................................................................................................................................................................................... 74
The particle is then released by exocytosis. ........................................................................................................................................................................................................................... 74

Genome packaging........................................................................................................................................................................................................ 74
Genome packaging signals (RNA genomes)............................................................................................................................................................................................................................ 75
Genome packaging signals (DNA genomes) ........................................................................................................................................................................................................................... 75
Packaging of segmented RNA genomes ................................................................................................................................................................................................................................. 76
Taking along a lipid coat on the way out................................................................................................................................................................................................................................. 76

Virion exit from the cell ................................................................................................................................................................................................. 77
Virus budding through the cellular exocytosis pathway ......................................................................................................................................................................................................... 78
Virus budding at the plasma membrane ................................................................................................................................................................................................................................ 78

Viral budding via host-assisted ESCRT complexes ........................................................................................................................................................... 78
ESCRT-independent budding à exam !! ............................................................................................................................................................................................................................... 78

Cell-to-cell transport...................................................................................................................................................................................................... 79

Virus maturation (example Dengue) ............................................................................................................................................................................. 79

Virus maturation (example HIV) .................................................................................................................................................................................... 79

Virus evolution ...........................................................................................................................................................................................80
Genomic epidemiology of Ebola virus in DRC ................................................................................................................................................................. 80

Genomic epidemiology of SARS-CoV-2 ........................................................................................................................................................................... 80

Phylogenetics ............................................................................................................................................................................................................... 81

Virus evolution and main drivers of evolution ................................................................................................................................................................ 81
RNA virus evolution ............................................................................................................................................................................................................................................................... 81
DNA virus evolution (it is a bit like are our genomes + quite stable) ...................................................................................................................................................................................... 82




3

, The quasispecies concept .............................................................................................................................................................................................. 82

Diversity is selected but also has limits .......................................................................................................................................................................... 84
The error treshold – hypermutation pushed by ribavirin ....................................................................................................................................................................................................... 84
Genetic bottlenecks ............................................................................................................................................................................................................................................................... 84
Genetic bottlenecks in real life ............................................................................................................................................................................................................................................... 85
Avoiding the ‘ratchet’ in real life ............................................................................................................................................................................................................................................ 85

Virus-host arms race...................................................................................................................................................................................................... 86
An experiment in the evolution of virulence .......................................................................................................................................................................................................................... 86
The arms race ........................................................................................................................................................................................................................................................................ 88

Evolution of virulence – more recent examples .............................................................................................................................................................. 88
Virus evolution ...................................................................................................................................................................................................................................................................... 88
Constraints on virus evolution à viral genome cannot change infinitely ............................................................................................................................................................................... 88

In summary................................................................................................................................................................................................................... 89

Emerging & re-emerging viruses .................................................................................................................................................................90
WHO pathogen priority list .................................................................................................................................................................................................................................................... 90

Major drivers of virus emergence and spread ................................................................................................................................................................ 90

Obligate intracellular parasites with small genomes & high mutation rates .................................................................................................................... 92

Zoonotic origin .............................................................................................................................................................................................................. 92

viral hemorrhagic fevers ............................................................................................................................................................................................... 92

Ebolavirus ..................................................................................................................................................................................................................... 93

Ebola virus replication cycle........................................................................................................................................................................................... 95

Clinical course of acute Ebola Virus Disease (slide 16) .................................................................................................................................................... 96

A history of outbreaks in Central Africa.......................................................................................................................................................................... 97

Zoonotic origin of EBOV................................................................................................................................................................................................. 97

Ebola virus genetic diversity and reservoir species?........................................................................................................................................................ 97

Distribution of suspected EBOV-carrying fruit bats ......................................................................................................................................................... 98

Intermediate and/or amplifying host? ........................................................................................................................................................................... 98

Relapse – a new paradigm for starting Ebola virus outbreaks ......................................................................................................................................... 98

The 2013-2016 EBOV outbreak in West Africa ................................................................................................................................................................ 99

VHF outbreak potential in Africa (and beyond) .............................................................................................................................................................. 99

Ebola virus transmission cycles ...................................................................................................................................................................................... 99
Human to human transmission ............................................................................................................................................................................................................................................ 100

Human demographics: Central Africa vs. West Africa ................................................................................................................................................... 100

Extremely weak health care systems & slow response ................................................................................................................................................. 100

2013-2016 EBOV outbreak origin and ignition .............................................................................................................................................................. 101

The 2013-2016 EBOV outbreak evolution ..................................................................................................................................................................... 101

GP A82V mutation – an example of EBOV adaptation to humans ................................................................................................................................. 102

GP A82V confers increased infectivity in human cells ................................................................................................................................................... 102

Association between GP A82V and increased rate of lethal infection............................................................................................................................ 102

A82V sensitizes EBOV GP to activation by the NPC1 receptor… ..................................................................................................................................... 103
…but does not alter pathogenicity in two animal models .................................................................................................................................................................................................... 103

Improvements since the West Africa Ebola outbreak ................................................................................................................................................... 103

Laboratory diagnosis of Ebola virus disease ................................................................................................................................................................. 104
Xpert® Ebola Assay (Cepheid) .............................................................................................................................................................................................................................................. 104


4

Table of contents

  1. 01 An introduction to virology 12
  2. 02 What are viruses? 12
  3. 03 Astonishing number of viruses on Earth à Viruses are everywhere 12
  4. 04 The human genome contains remnants of viral genetic material 14
  5. 05 Viruses are small 14
  6. 06 Viruses are diverse in structure 14
  7. 07 All viruses are obligatory parasites (they need to get into a cell !) 15
  8. 08 Virus replication 16
  9. 09 Viruses have high genome evolution rates 17
  10. 10 So, are viruses dead or alive 18
  11. 11 Most important reasons to exclude viruses from the tree of life 18
  12. 12 There are no ancestral viral lineages: 18
  13. 13 Viruses don’t have a structure derived from a common ancestor: 18
  14. 14 Origin of viruses à Three traditional scenario’s: 19
  15. 15 A typical virus genome à it is a nucleic acid code 20
  16. 16 A chimeric origin of viruses 20
  17. 17 Five hallmark viral replication genes 21
  18. 18 Cellular ancestry of capsids 21
  19. 19 A brief history of virology 22
  20. 20 Koch’s postulates !!! to affirm the causes of infectious diseases 22
  21. 21 21st century revised version of Koch’s postulates 23
  22. 22 Classification of viruses 23
  23. 23 !!!!!!!!! THE BALTIMORE SYSTEM 24
  24. 24 Definitions/rules underlying the Baltimore system 25
  25. 25 Class I: dsDNA genomes and gapped dsDNA genomes 26
  26. 26 Viruses with dsDNA genomes 26
  27. 27 Class II: ssDNA genomes 27
  28. 28 Viruses with ssDNA genomes 27
  29. 29 Viruses with RNA genomes 27
  30. 30 Class III: dsRNA genomes 28
  31. 31 Viruses with dsRNA genomes 28
  32. 32 Class IV: ss(+)RNA genomes 28
  33. 33 Class V: ss(-)RNA genomes 29
  34. 34 Class VI: ss(+)RNA genomes with a DNA intermediate 29
  35. 35 Class VII: dsDNA genomes with a RNA intermediate 30
  36. 36 Summary of 7 genome classes according to Baltimore 31
  37. 37 The virology toolbox 33
  38. 38 How can we say that a virus is present or not? 33
  39. 39 Virus isolation and propagation 33
  40. 40 Some important definitions and concepts 33
  41. 41 Virus isolation and propagation in cell culture 35
  42. 42 Viruses can induce formation of synctytia 35
  43. 43 Determining the number of viruses in a sample à 2 main methods 35
  44. 44 Multiplicity of infection (MOI) 37
  45. 45 Physical measurements of virus particles 38
  46. 46 Electron microscopy 38
  47. 47 Detecting viral antigens and antiviral antibodies 39
  48. 48 introduction part 2: Virus structures 40
  49. 49 A typical virus genome 40
  50. 50 Virus particles are made up from structural proteins Functions of structural proteins: 40
  51. 51 From larger to smaller blocks 40
  52. 52 Virus particles are metastable 40
  53. 53 basic virus structures 41
  54. 54 Symmetry is key to build virus particles Watson and Crick seminal observations: 41
  55. 55 Virus particles are metastable 41
  56. 56 Many capsid proteins are self-assembling in VLP (virus-like-particles) 41
  57. 57 Helical symmetry 42
  58. 58 Icosahedral symmetry (it is like crystals) 42
  59. 59 Simple icosahedral capsid 42
  60. 60 Capsids can be covered by host-derived lipid membranes (! This is not always) 43
  61. 61 why would a virus get an (extra) envelop (instead of a just capside)? 43
  62. 62 Viral envelope 44
  63. 63 Viral envelope glycoprotein 44
  64. 64 Complex symmetry 44
  65. 65 Replication cycles 46
  66. 66 Steps in virus replication 46
  67. 67 Virus attachment and entry 46
  68. 68 Cellular receptors for viruses 48
  69. 69 Criteria to identify virus receptors à EXAM QUESTION 48
  70. 70 Adhesion receptors and entry receptors 48
  71. 71 Virus attachment to host glycan polysaccharide 50
  72. 72 Virus attachment to host lectin 50
  73. 73 Strategies of how viruses enter cells 50
  74. 74 Fusion is a regulated process 50
  75. 75 Fusion of viral and plasma membranes at the cell surface (receptor mediated) 50
  76. 76 Fusion of virus membrane with host endosomal membrane 50
  77. 77 Non-enveloped virus entry and genome release 53
  78. 78 Active transportation through the cytosol 53
  79. 79 Modes of nuclear entry (mostly DNA viruses) 53
  80. 80 Genome transcription and translation 55
  81. 81 Some definitions 55
  82. 82 Rules for viral RNA synthesis 55
  83. 83 Universal rules for RNA-directed RNA synthesis 55
  84. 84 RdRp initiates RNA synthesis in two ways 56
  85. 85 Single stranded (+)RNA viruses 57
  86. 86 Single stranded (-)RNA viruses 57
  87. 87 dsRNA viruses (contain both + and – strands) 58
  88. 88 dsDNA transcription in DNA viruses 58
  89. 89 Cap snatching by influenza virus 59
  90. 90 Viral mRNA’s are polyadenylated at the 3’ end 59
  91. 91 Initiation of translation in eukaryotes 59
  92. 92 Initiation of translation of uncapped mRNA 59
  93. 93 What does IRES do? 60
  94. 94 Monocistronic and polycistronic mRNA’s 60
  95. 95 Viruses do all the same things that our proteins do à Post-translational modifications 62
  96. 96 Genome replication 64
  97. 97 Locations of virus genome replication in eukaryotic cells 64
  98. 98 Initiation of genome replication 64
  99. 99 DNA strand displacement replication 66
  100. 100 Key enzymes in RNA virus genome replication 66
  101. 101 Viral factories 67
  102. 102 ss(-)RNA virus replication (Filoviruses) 67
  103. 103 Reverse transcription 68
  104. 104 introduction part 3 69
  105. 105 Assembly and exit 69
  106. 106 The structure of a virion determines how it is formed 70
  107. 107 All virions complete a common set of assembly reactions 70
  108. 108 Moving cargo around the cytoplasm 70
  109. 109 How to get viral proteins in the right place for assembly? 71
  110. 110 Virus assembly is an ordered proces 71
  111. 111 (Nucleo)capsid assembly and genome packaging 71
  112. 112 Three strategies for making sub-assemblies 72
  113. 113 Some viruses assemble their capsid in the nucleus 72
  114. 114 Nuclear exit of the viral genome or nuclear capsid 73
  115. 115 Assisted genome export through nuclear pores 73
  116. 116 Genome export through nuclear egress (Herpesviruses) 74
  117. 117 The particle is then released by exocytosis 74
  118. 118 Genome packaging 74
  119. 119 Genome packaging signals (RNA genomes) 75
  120. 120 Genome packaging signals (DNA genomes) 75
  121. 121 Packaging of segmented RNA genomes 76
  122. 122 Taking along a lipid coat on the way out 76
  123. 123 Virion exit from the cell 77
  124. 124 Virus budding through the cellular exocytosis pathway 78
  125. 125 Virus budding at the plasma membrane 78
  126. 126 Viral budding via host-assisted ESCRT complexes 78
  127. 127 ESCRT-independent budding à exam !! 78
  128. 128 Cell-to-cell transport 79
  129. 129 Virus maturation (example Dengue) 79
  130. 130 Virus maturation (example HIV) 79
  131. 131 Virus evolution 80
  132. 132 Genomic epidemiology of Ebola virus in DRC 80
  133. 133 Genomic epidemiology of SARS-CoV-2 80
  134. 134 Phylogenetics 81
  135. 135 Virus evolution and main drivers of evolution 81
  136. 136 RNA virus evolution 81
  137. 137 DNA virus evolution (it is a bit like are our genomes + quite stable) 82
  138. 138 The quasispecies concept 82
  139. 139 Diversity is selected but also has limits 84
  140. 140 The error treshold – hypermutation pushed by ribavirin 84
  141. 141 Genetic bottlenecks 84
  142. 142 Genetic bottlenecks in real life 85
  143. 143 Avoiding the ‘ratchet’ in real life 85
  144. 144 Virus-host arms race 86
  145. 145 An experiment in the evolution of virulence 86
  146. 146 The arms race 88
  147. 147 Evolution of virulence – more recent examples 88
  148. 148 Virus evolution 88
  149. 149 Constraints on virus evolution à viral genome cannot change infinitely 88
  150. 150 In summary 89
  151. 151 Emerging & re-emerging viruses 90
  152. 152 WHO pathogen priority list 90
  153. 153 Major drivers of virus emergence and spread 90
  154. 154 Obligate intracellular parasites with small genomes & high mutation rates 92
  155. 155 Zoonotic origin 92
  156. 156 viral hemorrhagic fevers 92
  157. 157 Ebolavirus 93
  158. 158 Ebola virus replication cycle 95
  159. 159 Clinical course of acute Ebola Virus Disease (slide 16) 96
  160. 160 A history of outbreaks in Central Africa 97
  161. 161 Zoonotic origin of EBOV 97
  162. 162 Ebola virus genetic diversity and reservoir species? 97
  163. 163 Distribution of suspected EBOV-carrying fruit bats 98
  164. 164 Intermediate and/or amplifying host? 98
  165. 165 Relapse – a new paradigm for starting Ebola virus outbreaks 98
  166. 166 The 2013-2016 EBOV outbreak in West Africa 99
  167. 167 VHF outbreak potential in Africa (and beyond) 99
  168. 168 Ebola virus transmission cycles 99
  169. 169 Human to human transmission 100
  170. 170 Human demographics: Central Africa vs. West Africa 100
  171. 171 Extremely weak health care systems & slow response 100
  172. 172 2016 EBOV outbreak origin and ignition 101
  173. 173 The 2013-2016 EBOV outbreak evolution 101
  174. 174 GP A82V mutation – an example of EBOV adaptation to humans 102
  175. 175 GP A82V confers increased infectivity in human cells 102
  176. 176 Association between GP A82V and increased rate of lethal infection 102
  177. 177 A82V sensitizes EBOV GP to activation by the NPC1 receptor 103
  178. 178 …but does not alter pathogenicity in two animal models 103
  179. 179 Improvements since the West Africa Ebola outbreak 103
  180. 180 Laboratory diagnosis of Ebola virus disease 104
  181. 181 Xpert® Ebola Assay (Cepheid) 104
  182. 182 Rapid Diagnostic Tests for EVD diagnosis 105
  183. 183 Field performance of Ebola RDTs during 2018-2020 DRC outbreak 105
  184. 184 The ebola treatment unit 105
  185. 185 Vaccines and therapeutics in different phases of development 106
  186. 186 Ebola vaccines 107
  187. 187 Marburg virus: another filovirus causing sporadic outbreaks in humans 107
  188. 188 Arenaviridae 108
  189. 189 New World arenaviruses 108
  190. 190 Old World arenavirus - Lassa virus 108
  191. 191 Lassa virus genomic diversity complicates diagnostics 109
  192. 192 Lassa virus transmission 109
  193. 193 replication cycle 109
  194. 194 Lassa virus medical countermeasures 110
  195. 195 Emerging & re-emerging viruses – FLAVIVIRUSES 111
  196. 196 Clinically indistinguisable febrile syndrome & co-circulation 112
  197. 197 Epidemic drivers 113
  198. 198 Environmental suitability for Dengue occurence 113
  199. 199 types of mosquito vectors à aegypti & albopictus: 113
  200. 200 Environmental suitability for dengue occurence in Europe 113
  201. 201 Dengue virus 114
  202. 202 Dengue transmission 115
  203. 203 Arbovirus infection, dissemination and transmission 116
  204. 204 Flavivirus replication cycle à they replicate in different hosts! 116
  205. 205 Flavivirus genome structure = single molecule 117
  206. 206 NS1 in dengue pathogenesis 121
  207. 207 Antibody contributions to dengue protection and pathology 121
  208. 208 T-cell contributions to dengue protection and pathology 121
  209. 209 Antiviral treatments – none approved for dengue today 124
  210. 210 Zika virus 125
  211. 211 Zika virus co-occurrence with dengue 125
  212. 212 Zika virus symptoms and pathology (bit milder than with Dengue virus) 125
  213. 213 Zika virus transmission cycles 125
  214. 214 Vertical transmission and congenital disease induced by Zika virus 126
  215. 215 Clinical and Imaging Findings of Congenital Zika Syndrome 126
  216. 216 Slide 47: Timescale of Zika virus introduction in the Americas 126
  217. 217 Establishment and spread in the Americas – NE Brazil is epicentre 127
  218. 218 Southern Florida has a high potential for Ae. aegypti-borne virus outbreaks 127
  219. 219 Zika virus in France, Oct 2019 128
  220. 220 Yellow fever virus 129
  221. 221 Yellow fever pathogenesis 129
  222. 222 Live-attenuated Yellow fever vaccine (! Very good vaccine) 129
  223. 223 Slide 9: YF-17D backbone as vaccine platform 130
  224. 224 Yellow fever–Zika chimeric virus vaccine candidate 131
  225. 225 Slide 11: Yellow fever–Zika chimeric virus vaccine candidate 131
  226. 226 Avoiding antibody-dependent enhancement? 131
  227. 227 NS1-based Zika vaccine protects through T cell immunity 132
  228. 228 Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination 132
  229. 229 West nile 133
  230. 230 Rapid spread of WNV in the Americas 133
  231. 231 Vaccine preventable emerging flaviviruses 134
  232. 232 Why need to diagnose? 134
  233. 233 Clinically indistinguishable febrile syndromes complicate diagnosis 134
  234. 234 Dengue molecular diagnostic 135
  235. 235 Slide 28: IdyllaTM Molecular Diagnostic Platform 135
  236. 236 Unbiased approach for viral genome detection 137
  237. 237 Diagnosis of arbovirus infections à Antigen detection 137
  238. 238 Principle of lateral flow tests for NS1 antigen detection 138
  239. 239 Detecting anti-viral antibodies 138
  240. 240 Rapid diagnostic tests (RDTs) for dengue diagnosis 138
  241. 241 High degree of cross-reactivity with current serology tests for arboviruses 139
  242. 242 Emerging & re-emerging viruses – ALPHAVIRUSES 141
  243. 243 Chikungunya 141
  244. 244 Geographic spread of (re)emerging alphaviruses 141
  245. 245 Chikungunya virus replication cycle 142
  246. 246 Disease course of arthritogenic alphaviruses 143
  247. 247 Typical symptoms of acute CHIKV infection 143
  248. 248 Potential mechanisms of arthritic immunopathology in chikungunya (information) 143
  249. 249 Chikungunya virus outbreaks 144
  250. 250 E1-A226V increases vector competence of Aedes albopictus 144
  251. 251 introduction in the Americas 144
  252. 252 vaccines 144
  253. 253 Other emerging alphaviruses 145
  254. 254 Mayaro virus 145
  255. 255 Is Europe at risk for Mayaro virus outbreak (due to e.g. climate change)? 145
  256. 256 Eastern Equine Encephalitis virus on the rise in the USA 145
  257. 257 Oropouche virus 145
  258. 258 Oropouche virus replication cycle 146
  259. 259 Factors driving virus (re)emergence 146
  260. 260 Respiratory viruses 147
  261. 261 Respiratory tract 149
  262. 262 Bronchitis / bronchiolitis 149
  263. 263 Pneumonia 149
  264. 264 Common cold 149
  265. 265 Croup 150
  266. 266 Influenza-like illness = very broad term 150
  267. 267 Viral cause of RTI 150
  268. 268 General overview 151
  269. 269 Respiratory Virus transmission 152
  270. 270 aerosol deposition 153
  271. 271 Respiratory Virus seasonality 154
  272. 272 humidity/temp (EXAM!!) 155
  273. 273 RSV – Respiratory Syncytial Virus 156
  274. 274 Pneumoviridae 157
  275. 275 Epidemiology 158
  276. 276 Treatment 158
  277. 277 Prevention 158
  278. 278 Human Metapneumovirus (hMPV) 159
  279. 279 Pneumoviridae 159
  280. 280 Adenovirus/HboV 159
  281. 281 Adenoviridae 160
  282. 282 Epidemiology 161
  283. 283 Parainfluenzavirus – PIV3 – PIV1 162
  284. 284 Paramyxoviridae 162
  285. 285 Epidemiology 163
  286. 286 Treatment and prevention 164
  287. 287 Rhinovirus & non-rhinovirus enteroviruses 165
  288. 288 Picornaviridae 165
  289. 289 Picornaviridae – genus enterovirus (rhinovirus) 165
  290. 290 Epidemiology 166
  291. 291 Treatment & prevention 166
  292. 292 Non-rhinovirus enteroviruses 167
  293. 293 Enterovirus D68 167
  294. 294 Impact of Covid-19 NPI on epidemiology of respiratory viruses 168
  295. 295 Influenza lineage extinction during the COVID-19 pandemic? 169
  296. 296 Herpesviruses 170
  297. 297 Classification 170
  298. 298 Main characteristics (!! Exam) 170
  299. 299 Herpesviridae 171
  300. 300 Classification – human herpesviruses !!!! 172
  301. 301 Virus structure 173
  302. 302 HSV-1 – Human Herpesvirus 1 (HHV-1) 173
  303. 303 Genome 173
  304. 304 Replication cycle 174
  305. 305 HHV-1 176
  306. 306 Herpesviral encephalitis and herpesviral meningitis 177
  307. 307 Epidemiology 177
  308. 308 HHV-2 177
  309. 309 Pathogenesis 177
  310. 310 Epidemiology 178
  311. 311 HHV-3 178
  312. 312 Course of infection – latency – reactivation 179
  313. 313 HHV-5 - Cytomegalovirus – CMV 180
  314. 314 Congenital CMV infection = multisystemic 181
  315. 315 HHV-4 - Epstein Barr Virus – EBV 182
  316. 316 Pathogenesis 182
  317. 317 HHV6A/B – HHV7 183
  318. 318 HHV-8 - Kaposi sarcoma associated herpes virus (KSHV) 183
  319. 319 COVID 184
  320. 320 Virology 184
  321. 321 Class IV: Positive single stranded (+ ss) RNA viruses 184
  322. 322 Emerging Human Coronavirus Infections since the sixties 185
  323. 323 The origin of human SARS-like Coronaviruses 185
  324. 324 Coronaviruses and their associated diseases 186
  325. 325 SARS-CoV-2 structure and genetic organisation 186
  326. 326 Entry process of SARS-CoVs 187
  327. 327 Two Entry Pathways of SARS-CoV-2 188
  328. 328 Expression of ACE-2 throughout the body 188
  329. 329 SARS-CoV-2 = + RNA virus with “complex cycle” 188
  330. 330 Genomic organization of SARS-CoV-2 189
  331. 331 NSP3 papain-like protease PLpro and NSP5 3-chymotrypsin-like 3CL pro (also referred to as Mpro) 189
  332. 332 Genomic organisation and function of various non-structural proteins (nsp) of SARS-CoV-2 189
  333. 333 Genetic evolution in Spike protein across the « variants of concern » (VOC) 190
  334. 334 Headlines Virology SARS-CoV-2 192
  335. 335 Clinical aspects 193
  336. 336 COVID-19 Symptoms from head to toe 193
  337. 337 Summary of laboratory changes in patients with severe or fatal COVID-19 & Risk factors 195
  338. 338 Proposed clinical classification of COVID-19 disease spectrum 195
  339. 339 Treatment in patients at risk for complications and with severe disease 196
  340. 340 Multisystem Inflammatory Syndrome in Children (MIS-C) à it is a systematic disease 196
  341. 341 Post-acute COVID syndrome (PACS) or “long COVID” 197
  342. 342 Clinical aspects summary 197
  343. 343 Diagnosis à not seen in lecture 198
  344. 344 Summary rapid antigen and antibody tests 199
  345. 345 Immunology 201
  346. 346 Overview and role of type 1 interferon 201
  347. 347 SARS-CoV-2 and type 1 (and 3) Interferon 201
  348. 348 Adaptive immunity and interplay between T and B cells 202
  349. 349 Adaptive immunity in SARS-CoV-2 202
  350. 350 Summary (! Interesting overview) 203
  351. 351 Role of infection-induced immunity 203
  352. 352 Conclusions on immunity during and after COVID 204
  353. 353 Vaccination 205
  354. 354 ways to produce a vaccine 205
  355. 355 Hybrid immunity 206
  356. 356 Imprinting 206
  357. 357 Vaccine platforms used for SARS-CoV-2 vaccine development 207
  358. 358 Platforms for SARS-CoV-2 vaccine 208
  359. 359 Success of mRNA vaccination: trick 1 modifications 208
  360. 360 Immune response to mRNA vaccines 209
  361. 361 Various Adenoviruses in clinical trial 209
  362. 362 Principle of adenovirus vector vaccines 210
  363. 363 Testing neutralizing antibodies by Plaque Reduction Neutralization Test (PRNT) 210
  364. 364 Imprinting (original antigenic sin) hampers recognition of new epitopes 212
  365. 365 Conclusions vaccines 213
  366. 366 Viral Hepatitis 214
  367. 367 What is hepatitis? 214
  368. 368 Central role of the liver in metabolism 214
  369. 369 Liver anatomy 215
  370. 370 Symptoms of acute hepatitis 215
  371. 371 Course of non-complicated acute hepatitis 215
  372. 372 Pathogenesis of acute hepatitis 217
  373. 373 Clinically useful liver function tests 217
  374. 374 Hemoglobin molecule 217
  375. 375 Hemoglobin metabolism in the liver 218
  376. 376 Hemoglobin metabolism: in context of excretion to feces and urine 218
  377. 377 Symptoms of acute hepatitis 218
  378. 378 Chronic hepatitis (in hepatitis B and C) 218
  379. 379 Ascites = fluid in peritoneum 219
  380. 380 Portal hypertension and esophageal varices 219
  381. 381 Hyper-NH3 and hepatic encephalopathy 220
  382. 382 Other signs of chronic hepatitis 220
  383. 383 Etiology Hepatitis 221
  384. 384 Hepatitis viruses belong to very different classes/ families and transmission pathways 221
  385. 385 Hepatitis A virus 222
  386. 386 replication cycle 222
  387. 387 Hepatitis E virus 224
  388. 388 replication cycle 225
  389. 389 Epidemiology 225
  390. 390 Hepatitis E virus and the global disease burden 226
  391. 391 Overview of clinical manifestations of HEV 226
  392. 392 HEPATITIS E VIRUS: clinical course 227
  393. 393 Hepatitis E and pregnancy 227
  394. 394 Hepatitis B virus 228
  395. 395 Genome 228
  396. 396 Replication cycle 230
  397. 397 Epidemiology 231
  398. 398 Pathogenesis 231
  399. 399 Typical course of self-limiting HBV: evidence in serum 231
  400. 400 vaccination 232
  401. 401 Different profiles between self-limiting and chronic HBV infection 232
  402. 402 Transmission 232
  403. 403 Prevention 233
  404. 404 Treatment 233
  405. 405 Hepatitis D Virus 234
  406. 406 Hepatitis Delta Structure 234
  407. 407 Importance 234
  408. 408 Hepatitis C virus 235
  409. 409 Genomic structure 235
  410. 410 Genotypes 236
  411. 411 viral cycle 236
  412. 412 clinical course 237
  413. 413 Transmission 237
  414. 414 Epidemiology 237
  415. 415 Physiopathology ~ Hep B (similar with differences) 238
  416. 416 More extra-hepatic complication than hep B 238
  417. 417 Hepatitis C virus: blood parameters 239
  418. 418 HBV vs. HCV: treatment 239
  419. 419 Hepatitis C potential targets for drug development (you don’t need to learn all these products by heart) 239
  420. 420 Overview hepatitis viruses 240
  421. 421 The human immunodeficiency virus 242
  422. 422 HIV – more than just one virus 242
  423. 423 Origins of HIV-2 242
  424. 424 HIV-1 – from local outbreak to global pandemic 244
  425. 425 HIV mucosal transmission and systemic dissemination 245
  426. 426 Genetic bottleneck during (sexual) transmission (slide 13) 246
  427. 427 Biological properties of the “transmitted virus” 246
  428. 428 Biological factors that reduce risk of HIV transmission 246
  429. 429 Biological factors that increase risk of HIV transmission 247
  430. 430 HIV disease course 247
  431. 431 HIV particle 248
  432. 432 HIV genomic structure 248
  433. 433 HIV transcripts and proteins 249
  434. 434 HIV replication cycle 249
  435. 435 HIV entry 249
  436. 436 HIV membrane glycoprotein 249
  437. 437 CD4 binding site & Phe43 cavity (slide 28) 250
  438. 438 CD4-induced conformational change 250
  439. 439 HIV replication cycle – reverse transcription 250
  440. 440 Reverse transcription 251
  441. 441 HIV RT – a heterodimeric enzyme 251
  442. 442 Genomic evolution rates 251
  443. 443 HIV mutation rates 252
  444. 444 Intra-patient HIV evolution 252
  445. 445 HIV replication cycle – integration (3rd step) 252
  446. 446 Modes of nuclear entry 252
  447. 447 Model for HIV nuclear import 252
  448. 448 HIV integrase (In) enzyme 253
  449. 449 HIV replication cycle – transcription & budding (4th stept, last one) 254
  450. 450 Tat and Rev regulatory proteins 254
  451. 451 HIV Rev 254
  452. 452 HIV Nef – “a swiss army knife” 255
  453. 453 HIV accessory proteins 255
  454. 454 HIV Protease (PR) 255
  455. 455 HIV budding at the cell membrane 256
  456. 456 Anti(retro)viral treatment 256
  457. 457 Antiretroviral therapy for HIV 256
  458. 458 HIV entry inhibitors 256
  459. 459 Antibodies directed to HIV glycoprotein 257
  460. 460 Fusion inhibitors 257
  461. 461 Blocking viral polymerase activities 257
  462. 462 Nucleoside analogues 258
  463. 463 Non-nucleoside analogues 258
  464. 464 Non-nucleoside reverse transcriptase inhibitors (NNRTI) 258
  465. 465 Anti-HIV drugs available for treatment 259
  466. 466 Curing HIV? Au revoir HIV reservoir 259
  467. 467 Immunotherapy for HIV to induce a state of long-term control 259
  468. 468 Cured HIV patients (slide 82) 259
  469. 469 Strategies towards and HIV cure 260
  470. 470 HIV prevention strategies 260
  471. 471 Pre-exposure prophylaxis (PrEP) 261
  472. 472 Topical application of antiviral product - Microbicides 261
  473. 473 Summary - Human Immunodeficiency Viruses 261
  474. 474 poxviruses 263
  475. 475 small pox 263
  476. 476 structure 263
  477. 477 replication cycle 263
  478. 478 clinical aspects 264
  479. 479 skin lesions 264
  480. 480 pathofysiology 265
  481. 481 vaccination 265
  482. 482 smallpox 265
  483. 483 adverse events 266
  484. 484 monkey pox 266
  485. 485 clinical aspects 266
  486. 486 risk for complications? 267
  487. 487 vaccination 267
  488. 488 varicell-zoster or hhv3 267
  489. 489 virology & pathogenesis 267
  490. 490 clinical signs and complications 268

Document information

Study
Uploaded on
February 10, 2026
Number of pages
272
Written in
2024/2025
Type
Summary
$10.74

Wrong document? Swap it for free Within 14 days of purchase and before downloading, you can choose a different document. You can simply spend the amount again.
Written by students who passed
Immediately available after payment
Read online or as PDF

Sold
4
Followers
0
Items
15
Last sold
3 months ago




Why students choose Stuvia

Created by fellow students, verified by reviews

Quality you can trust: written by students who passed their tests and reviewed by others who've used these notes.

Didn't get what you expected? Choose another document

No worries! You can instantly pick a different document that better fits what you're looking for.

Pay as you like, start learning right away

No subscription, no commitments. Pay the way you're used to via credit card and download your PDF document instantly.

Student with book image

“Bought, downloaded, and aced it. It really can be that simple.”

Alisha Student

Working on your references?

Create accurate citations in APA, MLA and Harvard with our free citation generator.

Working on your references?

Frequently asked questions